**INTRODUCTION**

- Despite recent advances, patients with squamous (SCC) NSCLC are still in need of treatment options with improved safety/efficacy across treatment settings.
- First-line treatment with nab-paclitaxel + carboplatin (nab-P/C) has demonstrated a favorable risk-benefit profile in patients with SCC NSCLC in a subset analysis of a phase III trial and is a recommended first-line treatment option for this patient population.\(^1\) In patients with SCC NSCLC, gemcitabine and docetaxel are the only recommended chemotherapy options for maintenance therapy (NCCN Category 2B).
- The ongoing phase III ABOUND.sqm study was initiated to evaluate the safety and efficacy of nab-P/C induction therapy in patients with SCC NSCLC.

**OBJECTIVE**

- This analysis assessed the safety of nab-P/C treatment in patients with advanced SCC NSCLC during the induction phase of the ABOUND.sqm study.

**METHODS**

- Follow-up period: approximately every 90 days for up to 1.5 years.
- Patients receiving maintenance therapy have better survival compared with those not receiving maintenance therapy.\(^3,5\)

**RESULTS**

**Baseline Characteristics**

- This analysis included 212 patients (Table 1).
- Most patients were male, white, and had ECOG performance status 1.

**Treatment Discontinuations and Exposure**

- Overall, 94 of 212 patients (44%) discontinued induction treatment.
- The median treatment duration was 12.14 weeks.
- In all treated patients, the median percentage of per-protocol dose of nab-paclitaxel was 75%.
- Dose modifications are summarized in Table 2.

**Safety**

- Grade 3/4 TEAEs of special interest were mainly hematologic (Figure 3).
- Grade 3 peripheral neuropathy was reported in 4% (8/212) of patients.

**DISCUSSIONS**

- In this interim evaluation of the ABOUND.sqm study, no new safety signals were identified in patients with SCC NSCLC receiving nab-paclitaxel-based induction therapy.
- The median treatment duration was 12.14 weeks.
- The nab-P/C tolerability profile observed in this analysis is consistent with that reported in the pivotal phase III study.

**ACKNOWLEDGEMENTS**

- The authors wish to thank the patients and caregivers who participated in this study.
- The authors received editorial and production support in the preparation of this poster from MediTech Media, Ltd. funded by Celgene Corporation. The authors are fully responsible for all content and editorial decisions for this poster.

**DISCLOSURES**

- The authors disclose no financial or other conflicts of interest relevant to this study.
- The authors disclose no financial or other conflicts of interest relevant to this study.

**REFERENCES**

4. EFFORT, an open-label, randomized, phase III trial of nab-paclitaxel in patients with non-small cell lung cancer (NSCLC) as second-line therapy; ECOG: Eastern Cooperative Oncology Group; PFS: Progression-free survival; OS: Overall survival; ORR: Overall response rate; SD: Stable disease; TEAE: Treatment-emergent adverse event.